BASILEA PHARMACEUTICA AG The webcast, along with presentation will be available online https://www.globenewswire.com/Tracker?data=M5T8lNCe6Kjpf1WVE8ulZg0GOQFU4g9rECsX3WAiNWCWAElXHS2ds6QHJRr43udPzBRrkhvwzf52a9NeSzq8bMwN-nv2-a5ABFISs2LnRGutCMUY1JAssbOVWj3nz91RWlhfglmFwZ5OqsGdlyqtpA== shortly after the event and accessible for three months.
About Basilea
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the medical needs of patients with cancer and infectious diseases. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. We are conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com https://www.globenewswire.com/Tracker?data=-VnecuzIIVUqePKDXjx7G72W88XJH-xJRufaGcznU0ZhZeKCm3vDhfNSBeon5KdetJW-foXuhkqEMpolxXkRFw== .
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. Derazantinib and lisavanbulin and their uses are investigational and have not been approved by a regulatory authority for any use. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in nonclinical/preclinical studies to humans is currently being evaluated.
For further information, please contact:
Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
Phone +41 61 606 1102
E-mail media_relations@basilea.com
investor_relations@basilea.com
This ad hoc announcement can be downloaded from www.basilea.com.
References
1. Basilea has in-licensed derazantinib from ArQule Inc., a wholly-owned
subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.
2. FIDES-01 study: ClinicalTrials.gov identifier NCT03230318
3. FIDES-02 study: ClinicalTrials.gov identifier NCT04045613
4. FIDES-03 study: ClinicalTrials.gov identifier NCT04604132
5. ClinicalTrials.gov identifier NCT02490800
6. B. M. Alexander, T. F. Cloughesy. Adult Glioblastoma. Journal of Clinical
Oncology 2017 (35), 2402-2409
7. IQVIA, March 2021. In-market sales reported as moving annual total (MAT)
in U.S. Dollar corrected for currency fluctuations.
8. Clinicaltrials.gov identifier NCT03471988
9. Basilea's ceftobiprole phase 3 program is funded in part (up to USD 134.2
million, which is approximately 70% of the total potential program costs)
with federal funds from the U.S. Department of Health and Human Services;
Office of the Assistant Secretary for Preparedness and Response;
Biomedical Advanced Research and Development Authority (BARDA), under
contract number HHSO100201600002C.
10. TARGET study: Clinicaltrials.gov identifier NCT03137173. J. S. Overcash.
C. Kim, R. Keech et al. Ceftobiprole compared with vancomycin plus
aztreonam in the treatment of acute bacterial skin and skin structure
infections: results of a phase 3, randomized, double-blind trial
(TARGET). Clinical Infectious Diseases 2020,
ciaa974; https://doi.org/10.1093/cid/ciaa974
11. ERADICATE study: Clinicaltrials.gov identifier NCT03138733. K. Hamed, M.
Engelhardt, M. E. Jones et al. Ceftobiprole versus daptomycin in
Staphylococcus aureus bacteremia: a novel protocol for a double-blind,
phase III trial. Future Microbiology 2020 (15), 35-48;
https://doi.org/10.2217/fmb-2019-0332Attachment
-- Press release (PDF)
https://ml-eu.globenewswire.com/Resource/Download/3b56b1c7-974f-4b98-b5cf-1d09b02273f2(END) Dow Jones Newswires
August 17, 2021 01:15 ET (05:15 GMT)
